Geode Capital Management
EPRX

Geode Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Geode Capital Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$185K Buy
25,613
+11,714
+84% +$94.3K ﹤0.01% 3935
2025
Q4 		$105K Buy
+13,899
New +$85.7K ﹤0.01% 4082

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management's EPRX Position: Q1 2026 in Review

Geode Capital Management increased its Eupraxia Pharmaceuticals (EPRX) stake by 84% in Q1 2026, buying an estimated $94.3K and bringing the position to 25,613 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #3935.

Geode Capital Management first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Geode Capital Management held 25,613 shares of Eupraxia Pharmaceuticals worth $185K as of Q1 2026.
  • Geode Capital Management bought 11,714 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $94.3K.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3935 holding.
  • Geode Capital Management first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.